DARE Q3'26 Earnings: EPS estimate is (0.13) USD
Dare Bioscience (DARE) will report Q3'26 earnings on November 16. Analysts expect $2.04M revenue and a loss of $0.13 per share. Results will be released after market close.
How this was made

The 30-second read
Why it matters
The negative EPS estimate sets expectations for a loss, likely prompting short‑term selling ahead of the earnings call.
Market read
The earnings preview provides new guidance for a small-cap biotech, offering limited but actionable insight for traders focused on micro‑caps.
What to watch
Potential upcoming clinical trial data or partnership announcements could offset the weak guidance.
Background
Dare Bioscience is a micro‑cap biotech listed on Nasdaq under the ticker DARE.
Ticker impact
Dare Bioscience announced its Q3'26 earnings estimate of (0.13) EPS and $2.04M revenue, the first public disclosure of these numbers.
likely downside pressure as investors price in the negative EPS forecast
The forecast shows a loss per share; historically such guidance leads to short-term sell pressure before the earnings call.
Market effects
Biotech sector may see modest pullback as a micro‑cap reports a loss forecast.
US small‑cap biotech segment could face slight negative sentiment.
Limited to investors tracking micro‑cap earnings; no broader market effect.
Counterpoint
If the company surprises to the upside, the stock could rally sharply from a low base.
Key entities
- companyDare Bioscience, Inc.
Biotech firm reporting Q3'26 earnings estimate.